±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³ Á¤À¯¼® ±³¼ö, Á¦41Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¼ö»ó
2015³â 07¿ù 01ÀÏ 09½Ã 23ºÐ ÀÔ·Â

[¿Óóµ¥Àϸ®] ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³(ÃÑÀå À̰­Çö) ¾Ï°ü¸®Á¤Ã¥Çаú Á¤À¯¼® ±³¼ö ¿¬±¸ÆÀ(½Ã½ºÅÛÁ¾¾ç»ý¹°Çаú ÀÌ»óÁø ±³¼ö)ÀÌ Áö³­ 6¿ù 19ÀÏ ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ ¡®Á¦41Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ¡¯¿¡¼­ ³ë¹ÙƼ½º Merit Award Çмú»ó ÃÖ¿ì¼ö»óÀ» ¼ö»óÇß´Ù°í 1ÀÏ ¹àÇû´Ù.


Á¤À¯¼® ±³¼ö ¿¬±¸ÆÀÀº µÎ°æºÎ¾Ï µ¿¹°¸ðµ¨¿¡¼­ À¯ÀüÀÚÄ¡·á¿Í Àú¿ë·® Ç×¾ÏÁ¦ÀÇ º´ÇÕ¿ä¹ýÀÇ È¿°ú ¹× ±âÀüÀ» Æò°¡ÇÏ´Â ¿¬±¸ÀÎ ¡®Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma¡¯¸¦ ¹ßÇ¥ÇÏ¿© ÀÌ »óÀ» ¼ö»óÇß´Ù.